Pedestrians wearing protective face masks, amid the coronavirus disease (COVID-19) pandemic, walk at a shopping district on the first day after the lifting of COVID-19 restrictions imposed on Tokyo and 17 other prefectures, in Tokyo, Japan, March 22, 2022. REUTERS/Kim Kyung-Hoon
TOKYO (Reuters) - An experimental treatment from Shionogi & Co Ltd has shown rapid clearance of the virus that causes COVID-19, according to new data, the Japanese drug maker said on Sunday.
The pill, S-217622, "demonstrated rapid clearance of the infectious SARS-CoV-2 virus", Shionogi said in a statement, citing Phase-2b results from the Phase II/III clinical trial of the drug.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
